Phase I/II – First Administration

454 trials 191 recruiting

Filter these 454 trials by condition, country, sponsor and more.

Open in Search →

A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting

2023-508590-89-00 Multiple Myeloma 2024-06-25
Treatment of difficult-to-heal wounds with stem cells included in a gel consistency dressing Recruiting

2023-505017-25-02 Hard-to-heal-wounds 2024-06-10
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting

2023-504251-27-00 Locally Advanced or Metastatic Solid Tumors Harboring a 2024-05-27
Safety, Tolerability, PK, PD, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia Recruiting

2023-505995-31-00 Glanzmann Thrombasthenia 2024-05-03
A Phase I/IIa multicenter study evaluating the safety and efficacy of CAR20(NAP)-T in patients with relapsed/refractory B cell lymphoma (CAR… Recruiting

2024-511844-18-00 Relapsed or refractory CD20+ diffuse large B-cell lymph 2024-05-02
A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip… Recruiting

2023-507305-33-00 Patients with ER+ HER2- advanced breast cancer and pati 2024-04-29
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory… Recruiting

2023-508355-39-00 Relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leu 2024-04-20
Phase I-IIa, randomized, controlled, open-label, single-center clinical trial to evaluate the safety, feasibility, and evidence of efficacy … Recruiting

2023-506913-23-00 Cleft lip and palate 2024-04-17
A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations Recruiting

2023-506759-51-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 2024-03-29
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd m… Recruiting

2023-505925-15-00 Patients with HER2-positive (HER2-pos) (cohort 1) or HE 2024-03-21
A study to assess the safety and efficacy of IPN10200 in adult participants with moderate to severe upper facial lines Recruiting

2024-512782-14-00 Treatment of Moderate to Severe Upper Facial Lines 2024-03-20
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants with Hearing Loss Due to Otoferlin Pathogenic Var… Recruiting

2024-511342-40-00 Congenital Hearing Loss Secondary to Biallelic Pathogen 2024-03-04
First in Human Study of TOS-358 in Adults with Soid Tumors Recruiting

2023-505346-26-01 9 main solid tumors – colorectal, cervical, endometrial 2024-02-19
Ph1/2 study of AVB-101 in Subjects with Frontotemporal Dementia with Progranulin Mutations (FTD-GRN) Recruiting

2023-509444-10-00 Frontotemporal Dementia With Progranulin Mutations (FTD 2024-02-08
A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting

2022-502741-10-00 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearra 2024-01-26
FIRST IN-HUMAN STUDY EVALUATING THE EFFECT OF VARIOUS DOSES OF ODM-212 IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMOURS Recruiting

2022-503061-29-00 Neoplasms benign malignant and unspecified (incl cysts 2024-01-22
A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting

2023-504807-94-00 Breast Cancer; Advanced solid tumors including but not 2023-12-26
A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in … Recruiting

2022-501941-63-00 Multiple myeloma 2023-12-13
Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting

2022-501997-20-00 participants with isolated methylmalonic acidemia (MMA) 2023-12-01
FIPO23 Phase I/II, multi center, Open Label, First-in-human, Dose Escalation and Expansion study to investigate the Safety, Pharmacokinetics… Recruiting

2023-505266-29-00 Advanced or metastatic solid tumors 2023-11-14
A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination … Recruiting

2023-504845-30-00 Solid malignancies 2023-10-05
A double-blind, placebo-controlled, randomised phase 1/2a study to evaluate the safety, tolerability and pharmacokinetics of single and rep… Recruiting

2023-505778-14-00 Age related hearing loss 2023-09-19
A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting

2022-502157-33-00 B-Cell Malignancies 2023-09-18
First-in-human, Phase 1/2, open-label, multicenter, dose-escalation and expansion study Recruiting

2022-502645-99-00 MTAP-deleted Advanced or Metastatic Solid Tumors 2023-08-09